Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts This week, 27 April 2025: Treatment-resistant hypertension Influenza transmission Nanoplastics in human brains Malaria elimination Chikungunya vaccine

Lung Cancer

Free Subscription Articles published in Lung Cancer Retrieve available abstracts of 400 articles: HTML format

Single Articles

April 2025
1. CHOUAID C, Bosquet L, Knott C, Li Z, et al
   Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study.
   Lung Cancer. 2025;203:108548.
   PubMed     Abstract available
   
   
   
2. BARSOUK A, Elghawy O, Watts A, Reed-Guy L, et al
   Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
   Lung Cancer. 2025;203:108551.
   PubMed     Abstract available
   
   
   
3. SHIRAISHI Y, Shimose T, Tobino K, Toi Y, et al
   Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
   Lung Cancer. 2025;203:108543.
   PubMed     Abstract available
   
   
   
4. VAES RDW, Cortiula F, Lyu S, Hiltermann TJN, et al
   Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model.
   Lung Cancer. 2025;203:108541.
   PubMed     Abstract available
   
   
   
5. PAN Y, Gu Q
   Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.
   Lung Cancer. 2025;203:108532.
   PubMed     Abstract available
   
   
   
6. SARKAR S, Choa E, Manzo LL, Richman I, et al
   Predictors and Uptake of Lung Cancer Screening in the US: An Integrative Literature Review.
   Lung Cancer. 2025;203:108529.
   PubMed     Abstract available
   
   
   
7. WU Q, Li Q, Qin Y
   A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.
   Lung Cancer. 2025;203:108533.
   PubMed     Abstract available
   
   
   
8. AVANCINI A, Giaj-Levra N, Minuti G, Pasqualini G, et al
   Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study.
   Lung Cancer. 2025;203:108531.
   PubMed     Abstract available
   
   
   
9. ROSENLUND L, Guldbrandsen K, Ahlborn LB, Bloch M, et al
   ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach.
   Lung Cancer. 2025;203:108528.
   PubMed     Abstract available
   
   
   
10. AN Z, Ning Y, Mei J, Yang C, et al
    Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma.
    Lung Cancer. 2025;202:108507.
    PubMed     Abstract available
    
    
    
11. TAKAMOCHI K, Suzuki K, Okada M, Niho S, et al
    CRES(3)T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors.
    Lung Cancer. 2025;202:108506.
    PubMed     Abstract available
    
    
    
12. FAN M, Yan W, Zhuo M, Yu R, et al
    Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report.
    Lung Cancer. 2025;202:108501.
    PubMed     Abstract available
    
    
    
13. MESSEKHER M, Fuchs F, Badr M, Pujol JL, et al
    Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report with 5-Year Follow-Up.
    Lung Cancer. 2025;202:108456.
    PubMed     Abstract available
    
    
    
14. AHUJA G, Iyer A, Harwood R, Balata H, et al
    Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.
    Lung Cancer. 2025;202:108493.
    PubMed     Abstract available
    
    
    
15. TORASAWA M, Yoshida T, Shiraishi K, Yagishita S, et al
    Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.
    Lung Cancer. 2025;202:108494.
    PubMed     Abstract available
    
    
    
16. LAVEN IEWG, Franssen AJPM, Gronenschild MHM, Heineman DJ, et al
    National clinical practice patterns of uniportal video-assisted thoracoscopic anatomical lung resections: nationwide population-based data from a clinical audit registry.
    Lung Cancer. 2025;202:108481.
    PubMed     Abstract available
    
    
    
17. GARASSINO MC, He Y, Ahn MJ, Orlov SV, et al
    Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
    Lung Cancer. 2025;202:108417.
    PubMed     Abstract available
    
    
    
18. KAWAKITA N, Takehara E, Takeuchi T, Fujimoto K, et al
    Advantages of a larger working channel diameter of ultrathin bronchoscope in cone-beam computed tomography-guided transbronchial biopsy for diagnosing peripheral lung lesions.
    Lung Cancer. 2025;202:108483.
    PubMed     Abstract available
    
    
    
19. SOO RA, Vervita K, Fruh M, Cho BC, et al
    A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
    Lung Cancer. 2025;202:108454.
    PubMed     Abstract available
    
    
    March 2025
20. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
    Stereotactic body radiation therapy (SBRT) of centrally located medically inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup analysis of the expanded HILUS study.
    Lung Cancer. 2025;203:108527.
    PubMed     Abstract available
    
    
    
21. LIU SV, Dziadziuszko R, Viteri S, Cappuzzo F, et al
    ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors.
    Lung Cancer. 2025;203:108516.
    PubMed    
    
    
    
22. ADDO S, Lycan T, Soto-Pantoja DR, Tsai YT, et al
    Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
    Lung Cancer. 2025;203:108513.
    PubMed     Abstract available
    
    
    
23. NARGUND RS, Ishizawa S, Eghbalizarch M, Yeh P, et al
    Natural history models for lung Cancer: A scoping review.
    Lung Cancer. 2025;203:108495.
    PubMed     Abstract available
    
    
    
24. ISAKA M, Notsu A, Kojima H, Konno H, et al
    Comparative validation of nodal classifications in resected non-small cell lung cancer based on the anatomical location and number of involved stations.
    Lung Cancer. 2025;203:108511.
    PubMed     Abstract available
    
    
    
25. KESKIN O
    Beyond the Staging: Critical Insights into the Ninth TNM Edition for Lung Cancer.
    Lung Cancer. 2025;203:108502.
    PubMed    
    
    
    
26. TRIWIYANTO T, Alit Pawana I, Luthfiyah S
    Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
    Lung Cancer. 2025;202:108512.
    PubMed    
    
    
    
27. CHEN H, Cai W, Han Y, Zhao Y, et al
    Associations between carbohydrate quality and the survival of, and life expectancy with lung cancer patient: A prospective cohort study.
    Lung Cancer. 2025;203:108508.
    PubMed     Abstract available
    
    
    
28. BOUSEMA JE, Spaans LN, Dijkgraaf MGW, van der Heijden EHFM, et al
    Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up).
    Lung Cancer. 2025;202:108462.
    PubMed     Abstract available
    
    
    
29. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
    Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention.
    Lung Cancer. 2025;202:108500.
    PubMed     Abstract available
    
    
    
30. GOTO Y, Watanabe S, Yanagimura N, Arita M, et al
    The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.
    Lung Cancer. 2025;202:108505.
    PubMed     Abstract available
    
    
    
31. GOBBINI E, Diallo MH, Pasquier D, Schneider S, et al
    Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.
    Lung Cancer. 2025;202:108499.
    PubMed     Abstract available
    
    
    
32. JABER G, Raffoul C, Diab T, Sinno S, et al
    ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a Rare Case.
    Lung Cancer. 2025;202:108497.
    PubMed     Abstract available
    
    
    
33. VAN DER WEL JWT, de Langen AJ
    Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.
    Lung Cancer. 2025 Mar 14:108490. doi: 10.1016/j.lungcan.2025.108490.
    PubMed     Abstract available
    
    
    
34. NAVEED F, Khan S, Khan A, Arshad F, et al
    Letter: Alectinib combined with cobimetinib in ALK-rearranged lung cancer: A phase IB study.
    Lung Cancer. 2025;202:108489.
    PubMed    
    
    
    
35. NOUSIAS O, Mandell JD, Anderson KS, Townsend JP, et al
    Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.
    Lung Cancer. 2025;202:108487.
    PubMed     Abstract available
    
    
    
36. SETO T, Nakane S, Ji L, Ueda Y, et al
    Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance.
    Lung Cancer. 2025;203:108478.
    PubMed     Abstract available
    
    
    
37. VERKOULEN KCHA, Laven IEWG, Daemen JHT, Franssen AJPM, et al
    From data to prediction: Digital chest drain insights into postoperative recovery after lung cancer surgery.
    Lung Cancer. 2025;202:108486.
    PubMed     Abstract available
    
    
    
38. CHO BC, Johnson M, Bar J, Schaefer E, et al
    A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
    Lung Cancer. 2025;202:108492.
    PubMed     Abstract available
    
    
    
39. COOKE S, Nelson D, Argin AA, Laparidou D, et al
    Identifying and exploring patient engagement interventions for people diagnosed with lung cancer: A rapid systematic review.
    Lung Cancer. 2025;202:108484.
    PubMed     Abstract available
    
    
    
40. VINAS F, Goussault H, Boyer L, Bussac GR, et al
    Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study).
    Lung Cancer. 2025;202:108480.
    PubMed     Abstract available
    
    
    
41. FROST MG, Jensen KJ, Jimenez-Solem E, Qvortrup C, et al
    Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study.
    Lung Cancer. 2025;202:108485.
    PubMed     Abstract available
    
    
    
42. GRIDELLI C, Attili I, Bennati C, Bironzo P, et al
    Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?
    Lung Cancer. 2025;202:108482.
    PubMed     Abstract available
    
    
    
43. IGLESIAS MARTINEZ B, Insa A, Cervera Ygual G, Gascon F, et al
    Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis.
    Lung Cancer. 2025;202:108464.
    PubMed     Abstract available
    
    
    
44. UEHARA Y, Izumi H, Kobayashi IS, Matsumoto S, et al
    Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).
    Lung Cancer. 2025;202:108479.
    PubMed     Abstract available
    
    
    
45. GROS L, Yip R, Flores RM, Zhang J, et al
    Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage 1A Non-Small cell lung cancer.
    Lung Cancer. 2025;202:108465.
    PubMed     Abstract available
    
    
    
46. ZHANG M, Deng C, Fu F, Li Y, et al
    Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data.
    Lung Cancer. 2025;201:108451.
    PubMed     Abstract available
    
    
    
47. MORIMOTO K, Yamada T, Furuya N, Tanaka H, et al
    Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
    Lung Cancer. 2025;201:108447.
    PubMed     Abstract available
    
    
    
48. CHOI W, Lee W, Kim Y, Lee SJ, et al
    Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma.
    Lung Cancer. 2025;201:108448.
    PubMed     Abstract available
    
    
    
49. SUBRAMANIAN J, Gregg J, Berktas M, Li J, et al
    EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database.
    Lung Cancer. 2025;201:108412.
    PubMed     Abstract available
    
    
    
50. CAMIDGE DR, Sugawara S, Kondo M, Kim HR, et al
    Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
    Lung Cancer. 2025;201:108424.
    PubMed     Abstract available
    
    
    
51. YAO Z, Qiu T, Li C, Kong W, et al
    Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases.
    Lung Cancer. 2025;201:108414.
    PubMed     Abstract available
    
    
    February 2025
52. SAW SPL, Takano A, Zhou S, Hlaing NO, et al
    EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.
    Lung Cancer. 2025;202:108463.
    PubMed     Abstract available
    
    
    
53. YANG YH, Kim HE, Park BJ, Lee JG, et al
    Patterns and preoperative risk factors of occult lymph node metastasis in clinical stage I lung cancer.
    Lung Cancer. 2025;202:108461.
    PubMed     Abstract available
    
    
    
54. MA Z, Fu F, Zhang Y, Chen H, et al
    Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study.
    Lung Cancer. 2025;201:108457.
    PubMed     Abstract available
    
    
    
55. BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
    Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
    Lung Cancer. 2025 Feb 22:108441. doi: 10.1016/j.lungcan.2025.108441.
    PubMed    
    
    
    
56. JOHNSON M, Younan D, Kent ST, Frias MM, et al
    Corrigendum to "Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)" [Lung Cancer 197 (2024) 107960].
    Lung Cancer. 2025 Feb 20:108440. doi: 10.1016/j.lungcan.2025.108440.
    PubMed    
    
    
    
57. LEE K, Kim TH, Yong Lee S, Lee YG, et al
    Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15).
    Lung Cancer. 2025;201:108455.
    PubMed     Abstract available
    
    
    
58. GIRARD N, Han JY, Soo RA, Wang K, et al
    Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis.
    Lung Cancer. 2025;201:108450.
    PubMed     Abstract available
    
    
    
59. SATOH H, Okuma Y, Shinno Y, Masuda K, et al
    Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies.
    Lung Cancer. 2025;202:108453.
    PubMed     Abstract available
    
    
    
60. SANKAR K, Mercer J, Jaeger EB, Godden J, et al
    DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer.
    Lung Cancer. 2025;201:108444.
    PubMed     Abstract available
    
    
    
61. SHAHNAM A, Davis A, Brown LJ, Sullivan I, et al
    Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.
    Lung Cancer. 2025;201:108421.
    PubMed     Abstract available
    
    
    
62. AHN B, Kim D, Ji W, Chun SM, et al
    Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies.
    Lung Cancer. 2025;201:108445.
    PubMed     Abstract available
    
    
    
63. HUANG L, Petersen RH
    Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy.
    Lung Cancer. 2025;201:108438.
    PubMed     Abstract available
    
    
    
64. BOSCH-BARRERA J, Estevez-Garcia P, Martin-Martorell P, Sabatier R, et al
    ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
    Lung Cancer. 2025;201:108105.
    PubMed     Abstract available
    
    
    
65. AKAMATSU H, Nishikawa T, Takeda Y, Misumi T, et al
    Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.
    Lung Cancer. 2025;201:108437.
    PubMed     Abstract available
    
    
    
66. HE Q, Jiang L, Xu Y, Wang M, et al
    Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2025;201:108425.
    PubMed     Abstract available
    
    
    
67. ATASEVER F, Sokucu SN, Satici C
    Letter to the editor concerning "Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis".
    Lung Cancer. 2025;201:108423.
    PubMed    
    
    
    
68. FICARRA S, Kang DW, Wilson RL, Gonzalo-Encabo P, et al
    Exercise medicine for individuals diagnosed with Lung Cancer: A systematic review and meta-analysis of health outcomes.
    Lung Cancer. 2025;201:108413.
    PubMed     Abstract available
    
    
    
69. UPRETY D, Abrahami D, Marcum ZA, Li B, et al
    Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study.
    Lung Cancer. 2025;201:108436.
    PubMed     Abstract available
    
    
    
70. TAMBO Y, Sone T, Nishi K, Shibata K, et al
    Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score >/=50 %: A multicenter observational study.
    Lung Cancer. 2025;201:108422.
    PubMed     Abstract available
    
    
    
71. SUMI T, Ishigooka T, Matsuura K, Ikeda T, et al
    Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report.
    Lung Cancer. 2025;201:108420.
    PubMed     Abstract available
    
    
    
72. WANG Y, Fujita RA, Fujisawa N, Laskin J, et al
    Mitigation of decline with virtual exercise with lung cancer (MoVE with lung cancer) - A promising approach to enhance physiological strength, improve body composition, and build upon current evidence.
    Lung Cancer. 2025;201:108418.
    PubMed     Abstract available
    
    
    
73. IKEDA S, Ogura T, Miyaoka E, Sekine I, et al
    Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database.
    Lung Cancer. 2025;200:108102.
    PubMed     Abstract available
    
    
    
74. REUSS JE, Zaemes J, Gandhi N, Walker P, et al
    Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.
    Lung Cancer. 2025;200:108101.
    PubMed     Abstract available
    
    
    
75. HATA T, Yamada T, Goto Y, Amano A, et al
    Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
    Lung Cancer. 2025;200:108104.
    PubMed     Abstract available
    
    
    
76. NARITA D, Hishinuma E, Ebina-Shibuya R, Miyauchi E, et al
    Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile.
    Lung Cancer. 2025;200:108082.
    PubMed     Abstract available
    
    
    
77. GOMEZ-RANDULFE I, Scanlon LA, Carter M, Moliner L, et al
    First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
    Lung Cancer. 2025;200:108084.
    PubMed     Abstract available
    
    
    January 2025
78. DOBKIN J, Stanifer BP, Salvatore M, Eckhardt CM, et al
    Evaluating lung cancer risk factors in adults with interstitial lung disease.
    Lung Cancer. 2025;201:108416.
    PubMed     Abstract available
    
    
    
79. NISHI T, Morita A, Hara N, Makimoto G, et al
    Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines.
    Lung Cancer. 2025;201:108415.
    PubMed     Abstract available
    
    
    
80. LIU T, He J, Wang Y, Yang Y, et al
    Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double
    Lung Cancer. 2025;200:108108.
    PubMed     Abstract available
    
    
    
81. HOFMAN P, Ourailidis I, Romanovsky E, Ilie M, et al
    Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist.
    Lung Cancer. 2025;200:108110.
    PubMed     Abstract available
    
    
    
82. HOFMAN P, Christopoulos P, D'Haene N, Gosney J, et al
    Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer.
    Lung Cancer. 2025;201:108107.
    PubMed     Abstract available
    
    
    
83. AHMAD SQ, Pesola F, Crosbie PAJ, Gabe R, et al
    Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial.
    Lung Cancer. 2025;200:108086.
    PubMed     Abstract available
    
    
    
84. LEE KH, Lee JS, Sugawara S, Kang JH, et al
    First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
    Lung Cancer. 2025;201:108109.
    PubMed     Abstract available
    
    
    
85. MUNOZ OM, Delgado Leon BD, Selles EG, Enguix-Riego MV, et al
    Association of single nucleotide polymorphisms rs7459185 of the HSPbeta1 gene and the risk of hematological toxicity in lung cancer.
    Lung Cancer. 2025;200:108103.
    PubMed     Abstract available
    
    
    
86. GRIDELLI C, Mok T, Janne P, Passaro A, et al
    Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT).
    Lung Cancer. 2025;201:108100.
    PubMed     Abstract available
    
    
    
87. FUJII K, Ueki M, Morishita M, Ikushima H, et al
    Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database.
    Lung Cancer. 2025;200:108099.
    PubMed     Abstract available
    
    
    
88. MULLALLY WJ, O'Leary CG, O'Byrne KJ
    Rearranged during transfection (RET) lung cancer - Update on targeted therapies.
    Lung Cancer. 2025;200:108083.
    PubMed     Abstract available
    
    
    
89. DECOSTER L, Camidge DR, Fletcher JA, Addeo A, et al
    Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group.
    Lung Cancer. 2025;200:108087.
    PubMed     Abstract available
    
    
    
90. WU L, Tian JY, Li MJ, Jiang F, et al
    Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A multicenter study.
    Lung Cancer. 2025;200:108085.
    PubMed     Abstract available
    
    
    
91. TESEMA GA, Stirling RG, Wah W, Tessema ZT, et al
    Geographic variation in delay to surgical treatment among non-small cell lung cancer patients.
    Lung Cancer. 2025;199:108077.
    PubMed     Abstract available
    
    
    
92. LI Y, Law J, Le LW, Li JJN, et al
    Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.
    Lung Cancer. 2025;199:108080.
    PubMed     Abstract available
    
    
    
93. WU Y, Tang Y, Huang W, Zhu C, et al
    Improving the screening ability of neuron-specific enolase on small cell lung cancer.
    Lung Cancer. 2025;199:108078.
    PubMed     Abstract available
    
    
    
94. FUJIMOTO D, Shibaki R, Kimura K, Haratani K, et al
    Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
    Lung Cancer. 2025;199:108079.
    PubMed     Abstract available
    
    
    
95. SAW SPL, Zhong WZ, Fu R, Li MSC, et al
    Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
    Lung Cancer. 2025;200:108076.
    PubMed     Abstract available
    
    
    
96. NANAMI H, Matsumoto Y, Furuse H, Tanaka M, et al
    Efficacy of cryobiopsy during medical thoracoscopy for diagnosing malignant pleural mesothelioma.
    Lung Cancer. 2025;199:108074.
    PubMed     Abstract available
    
    
    
97. THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al
    A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers.
    Lung Cancer. 2025;199:108060.
    PubMed     Abstract available
    
    
    
98. TSUI DCC, Lee JK, Tambaoan CFB, Hughes J, et al
    Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
    Lung Cancer. 2025;199:108081.
    PubMed     Abstract available
    
    
    
99. WU M, Zhou N, Guan M, Wang Y, et al
    Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53.
    Lung Cancer. 2025;199:108068.
    PubMed     Abstract available
    
    
    
100. SHIELDS MD, Minton KG, Tran M, Gunderman PR, et al
     Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.
     Lung Cancer. 2025;199:108035.
     PubMed     Abstract available
     
     
     
101. VOLMONEN KK, Ronty MJ, Sederholm A, Paajanen JI, et al
     Evaluating tumour budding could improve the new grading system for lung adenocarcinoma.
     Lung Cancer. 2025;199:108067.
     PubMed     Abstract available
     
     
     
102. LEI M, Zhang X, Hu LN, Fu S, et al
     Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma.
     Lung Cancer. 2025;199:108057.
     PubMed     Abstract available
     
     
     
103. DE GIGLIO A, De Biase D, Favorito V, Maloberti T, et al
     STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.
     Lung Cancer. 2025;199:108058.
     PubMed     Abstract available
     
     
     
104. HE L, Zhang B, Zhou C, Zhao Q, et al
     A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules.
     Lung Cancer. 2025;199:108064.
     PubMed     Abstract available
     
     
     December 2024
105. OGLIARI FR, Traverso A, Barbieri S, Montagna M, et al
     Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience.
     Lung Cancer. 2024;199:108075.
     PubMed     Abstract available
     
     
     
106. NAKAO M, Suzuki A, Ichinose J, Matsuura Y, et al
     Prognostic impact of the N2 subclassification and stage migration in the ninth edition of the TNM classification in surgically resected lung cancer.
     Lung Cancer. 2024;199:108073.
     PubMed     Abstract available
     
     
     
107. AGUADO-BARRERA ME, Lopez-Pleguezuelos C, Gomez-Caamano A, Calvo-Crespo P, et al
     Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.
     Lung Cancer. 2024;199:108072.
     PubMed     Abstract available
     
     
     
108. HARRIS RA, Stokes EA, Batchelor TJP, Internullo E, et al
     Optimum diagnostic pathway and pathologic confirmation rate of early stage lung cancer: Results from the VIOLET randomised controlled trial.
     Lung Cancer. 2024;199:108070.
     PubMed     Abstract available
     
     
     
109. SZTANKOVICS D, Szalai F, Moldvai D, Danko T, et al
     Comparison of molecular subtype composition between independent sets of primary and brain metastatic small cell lung carcinoma and matched samples.
     Lung Cancer. 2024;199:108071.
     PubMed     Abstract available
     
     
     
110. WELLER M, Le Rhun E, Tsamtsouri L, Dummer R, et al
     Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study.
     Lung Cancer. 2024;199:108069.
     PubMed    
     
     
     
111. SUAZO-ZEPEDA E, Viddeleer AR, Maas WJ, Postmus D, et al
     CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis.
     Lung Cancer. 2024;199:108054.
     PubMed     Abstract available
     
     
     
112. ZERDES I, Kamali C, Johannsdottir B, Blasi M, et al
     A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers.
     Lung Cancer. 2024;199:108065.
     PubMed     Abstract available
     
     
     
113. MA Z, Liu Y, Bao Y, Wang M, et al
     Impact of locoregional recurrence versus distant metastasis on overall survival in patients with Non-Small cell lung cancer after Surgery: A secondary analysis of PORT-C RCT.
     Lung Cancer. 2024;199:108063.
     PubMed     Abstract available
     
     
     
114. DONG Y, Yang G, Yang Y, Zhang S, et al
     Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study.
     Lung Cancer. 2024;200:108062.
     PubMed     Abstract available
     
     
     
115. HOUDA I, Bahce I, Dickhoff C, Kroese TE, et al
     An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.
     Lung Cancer. 2024;199:108061.
     PubMed     Abstract available
     
     
     
116. GELSOMINO F, Boni L, Tiseo M, Ricciardi S, et al
     An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-201
     Lung Cancer. 2024;199:108059.
     PubMed     Abstract available
     
     
     
117. SUGISAKA J, Fujimoto D, Tamiya M, Hata A, et al
     Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
     Lung Cancer. 2024;199:108056.
     PubMed     Abstract available
     
     
     
118. URTECHO SB, Provenzano L, Spagnoletti A, Bottiglieri A, et al
     Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
     Lung Cancer. 2024;199:108051.
     PubMed     Abstract available
     
     
     
119. WANG M, Xu Y, Huang WT, Su WC, et al
     Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations.
     Lung Cancer. 2024;199:108053.
     PubMed     Abstract available
     
     
     
120. KARAYAMA M, Suda T, Yoh K, Usui K, et al
     Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
     Lung Cancer. 2024;198:108037.
     PubMed     Abstract available
     
     
     
121. FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al
     Diagnostic performance of Shape-Sensing Robotic-Assisted bronchoscopy with mobile Cone-Beam CT for cystic and cavitary pulmonary lesions.
     Lung Cancer. 2024;198:108029.
     PubMed     Abstract available
     
     
     
122. JOHN A, McMahon DJ, Chauhan D, Mullings S, et al
     Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care.
     Lung Cancer. 2024;198:108034.
     PubMed     Abstract available
     
     
     
123. AYOADE O, Canavan ME, Caturegli G, Boffa DJ, et al
     Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
     Lung Cancer. 2024;198:108032.
     PubMed     Abstract available
     
     
     
124. HEIJBOER FWJ, Mulders TA, van Straten M, Moonen L, et al
     Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure?
     Lung Cancer. 2024;198:108030.
     PubMed     Abstract available
     
     
     
125. VAN DER WEL JWT, Jebbink M, van den Broek D, Steinbusch LC, et al
     Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
     Lung Cancer. 2024;198:107972.
     PubMed     Abstract available
     
     
     
126. WANG L, Song B, Zhang Z, Bo B, et al
     Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial.
     Lung Cancer. 2024;198:108025.
     PubMed     Abstract available
     
     
     
127. SANTARPIA M, Aliprandi M, Claudia Spagnolo C, Avan A, et al
     NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma.
     Lung Cancer. 2024;198:108024.
     PubMed     Abstract available
     
     
     November 2024
128. SWALDUZ A, Beau-Faller M, Planchard D, Mazieres J, et al
     Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
     Lung Cancer. 2024;199:108038.
     PubMed     Abstract available
     
     
     
129. AUCLIN E, Roulleaux Dugage M, Gorria T, Vauchier C, et al
     Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials.
     Lung Cancer. 2024;199:108039.
     PubMed     Abstract available
     
     
     
130. PATIL T, Gao D, Watson A, Sakamoto M, et al
     The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
     Lung Cancer. 2024;199:108040.
     PubMed     Abstract available
     
     
     
131. JUNG W, Cho IY, Jeon KH, Yeo Y, et al
     Addressing knowledge and attitude barriers to lung cancer screening: Development and evaluation of web-based decision aid.
     Lung Cancer. 2024;198:108031.
     PubMed     Abstract available
     
     
     
132. ZENG H, Schagen SB, Hendriks LEL, Sanchez-Benavides G, et al
     Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.
     Lung Cancer. 2024;199:108036.
     PubMed     Abstract available
     
     
     
133. YU Z, Zou J, Xu F
     The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance.
     Lung Cancer. 2024;198:108033.
     PubMed     Abstract available
     
     
     
134. BAHADORI S, Hosseini M
     Use of commercial WAMs for monitoring individual with lung cancer. A systematic review.
     Lung Cancer. 2024;198:108026.
     PubMed     Abstract available
     
     
     
135. OSATAPHAN S, Awidi M, Jan YJ, Gunturu K, et al
     Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
     Lung Cancer. 2024;198:108023.
     PubMed     Abstract available
     
     
     
136. HORINOUCHI H, Murakami H, Harada H, Sobue T, et al
     Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
     Lung Cancer. 2024;199:108027.
     PubMed     Abstract available
     
     
     
137. KOSAKA N, Kataoka Y
     Letter regarding "The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma".
     Lung Cancer. 2024;198:108020.
     PubMed    
     
     
     
138. YU Y, Fan Y, Dong X, Li J, et al
     Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.
     Lung Cancer. 2024;198:108018.
     PubMed     Abstract available
     
     
     
139. LIU H, Hong Q, Zheng S, Zhang M, et al
     Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.
     Lung Cancer. 2024;198:108022.
     PubMed     Abstract available
     
     
     
140. AKAMATSU H, Koh Y, Nishio M, Goto Y, et al
     Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
     Lung Cancer. 2024;198:108017.
     PubMed     Abstract available
     
     
     
141. ZHANG B, Bao H, Li Z, Chen J, et al
     Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer.
     Lung Cancer. 2024;199:108021.
     PubMed     Abstract available
     
     
     
142. DONG J, Bao H
     Comment on: Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: A systematic literature review and meta-analysis of real-world evidence.
     Lung Cancer. 2024;201:108019.
     PubMed    
     
     
     
143. BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
     Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
     Lung Cancer. 2024 Nov 1:108000. doi: 10.1016/j.lungcan.2024.108000.
     PubMed    
     
     
     
144. TU X, Lu Z, Hei F, Zhang T, et al
     Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.
     Lung Cancer. 2024;197:107998.
     PubMed     Abstract available
     
     
     
145. HE X, Yang Z, Wu F, Liang Q, et al
     Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities.
     Lung Cancer. 2024;197:107994.
     PubMed     Abstract available
     
     
     
146. FILIPELLO F, Blaauwgeers H, Lissenberg-Witte B, Schonau A, et al
     Stereologic consequences of iatrogenic collapse: The morphology of adenocarcinoma in situ overlaps with invasive patterns. Proposal for a necessary modified classification of pulmonary adenocarcinomas.
     Lung Cancer. 2024;197:107987.
     PubMed     Abstract available
     
     
     
147. XU D, Liang SQ, Su M, Yang H, et al
     Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma.
     Lung Cancer. 2024;197:107986.
     PubMed     Abstract available
     
     
     
148. ZWIERENGA F, Zhang L, Melcr J, Schuuring E, et al
     The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.
     Lung Cancer. 2024;197:107973.
     PubMed     Abstract available
     
     
     
149. TABE C, Fujita T, Taima K, Tanaka H, et al
     Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
     Lung Cancer. 2024;197:107969.
     PubMed     Abstract available
     
     
     
150. SNIDER M, Salama JK, Boyer M
     Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC.
     Lung Cancer. 2024;197:107962.
     PubMed     Abstract available
     
     
     
151. BRUNE MM, Savic Prince S, Vlajnic T, Chijioke O, et al
     MTAP as an emerging biomarker in thoracic malignancies.
     Lung Cancer. 2024;197:107963.
     PubMed     Abstract available
     
     
     
152. UCHIBORI A, Okada S, Shimomura M, Furuya T, et al
     Clinical impact of preoperative sarcopenia and immunonutritional impairment on postoperative outcomes in non-small cell lung cancer surgery.
     Lung Cancer. 2024;198:108004.
     PubMed     Abstract available
     
     
     
153. DAGOGO-JACK I, Cooper AJ, Johnson BE, Gainor JF, et al
     Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
     Lung Cancer. 2024;199:108003.
     PubMed     Abstract available
     
     
     October 2024
154. VINCE M, Naqvi SMH, Pellini B, Verbosky M, et al
     Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
     Lung Cancer. 2024;198:107999.
     PubMed     Abstract available
     
     
     
155. PISAPIA P, Russo A, De Luca C, Pepe F, et al
     The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.
     Lung Cancer. 2024;198:108002.
     PubMed     Abstract available
     
     
     
156. PANG J, Zhang Y, Wang X, Wu W, et al
     Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS.
     Lung Cancer. 2024;197:108001.
     PubMed     Abstract available
     
     
     
157. CHAN YH, Yuen-Ting C, Sin CF, Ma ESK, et al
     Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming.
     Lung Cancer. 2024;197:107996.
     PubMed     Abstract available
     
     
     
158. AY L, Steiner D, Fabikan H, Illini O, et al
     Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis.
     Lung Cancer. 2024;198:107997.
     PubMed     Abstract available
     
     
     
159. LEVY A, Berghmans T, Koller M, Fournier B, et al
     PRIMALung (EORTC-1901): PRophylactic cerebral irradiation (PCI) or active brain MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC) patients.
     Lung Cancer. 2024;198:107993.
     PubMed     Abstract available
     
     
     
160. BERTOLACCINI L, Tralongo AC, Del Re M, Facchinetti F, et al
     Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes.
     Lung Cancer. 2024;197:107990.
     PubMed     Abstract available
     
     
     
161. TEIXIDOR-VILA E, Trallero J, Puigdemont M, Vidal-Vila A, et al
     Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.
     Lung Cancer. 2024;197:107995.
     PubMed     Abstract available
     
     
     
162. BAI Z, Cheng X, Ma T, Li G, et al
     CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients' prognosis treated with chemoimmunotherapy.
     Lung Cancer. 2024;197:107991.
     PubMed     Abstract available
     
     
     
163. KATO Y, Udagawa H, Matsumoto S, Izumi H, et al
     Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
     Lung Cancer. 2024;197:107992.
     PubMed     Abstract available
     
     
     
164. HATA A, Katakami N, Takase N, Kibata K, et al
     Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
     Lung Cancer. 2024;197:107988.
     PubMed     Abstract available
     
     
     
165. LI M, Soo RA
     Can therapeutic drug monitoring of lorlatinib help us design the right CROWN?
     Lung Cancer. 2024;196:107965.
     PubMed    
     
     
     
166. CHEN M, Huang Y, Jiang S, Ke C, et al
     Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
     Lung Cancer. 2024;196:107966.
     PubMed     Abstract available
     
     
     
167. ABIA-TRUJILLO D, Funes-Ferrada R, Yu Lee-Mateus A, Barrios-Ruiz A, et al
     Cryobiopsy versus fine-needle aspiration for shape-sensing robotic-assisted sampling of small lung nodules.
     Lung Cancer. 2024;196:107967.
     PubMed     Abstract available
     
     
     
168. SHIMODA IGAWA Y, Yoshida T, Makihara R, Torasawa M, et al
     Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.
     Lung Cancer. 2024;196:107954.
     PubMed     Abstract available
     
     
     
169. WATERHOUSE DM, Rothschild S, Dooms C, Mennecier B, et al
     Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
     Lung Cancer. 2024;196:107921.
     PubMed     Abstract available
     
     
     
170. ZHU C
     What's behind thoracic surgery explosion in young patients under the age of 40 in Wuhan after COVID-19 outbreak?
     Lung Cancer. 2024;196:107937.
     PubMed     Abstract available
     
     
     
171. YANG G, Chu Q
     Comment on: Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
     Lung Cancer. 2024;196:107938.
     PubMed    
     
     
     September 2024
172. OU SH, Kilvert H, Candlish J, Lee B, et al
     Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
     Lung Cancer. 2024;197:107968.
     PubMed     Abstract available
     
     
     
173. CHEN R, Donlon TA, Morris BJ, Allsopp RC, et al
     Association of alcohol with lung cancer risk in men with different growth hormone receptor genotypes.
     Lung Cancer. 2024;198:107971.
     PubMed     Abstract available
     
     
     
174. KANG DW, Park SK, Kang S, Lee EK, et al
     Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer.
     Lung Cancer. 2024;197:107970.
     PubMed     Abstract available
     
     
     
175. PLANCHARD D, Wolf J, Solomon B, Sebastian M, et al
     A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
     Lung Cancer. 2024;197:107964.
     PubMed     Abstract available
     
     
     
176. KAWAGUCHI K, Ogura T, Kaneda S, Watanabe T, et al
     A prospective multi-institutional study to verify the non-inferiority of postoperative pain in robot-assisted thoracic surgery in comparison with video-assisted thoracoscopic surgery for lung cancer: The Japanese RATS interest group 01 (J-RATSIG 01).
     Lung Cancer. 2024;196:107961.
     PubMed     Abstract available
     
     
     
177. LI L, Liu N, Zhou T, Qin X, et al
     A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy.
     Lung Cancer. 2024;196:107959.
     PubMed     Abstract available
     
     
     
178. SHIBAKI R, Fujimoto D, Miyauchi E, Tsukita Y, et al
     Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
     Lung Cancer. 2024;196:107958.
     PubMed     Abstract available
     
     
     
179. JOHNSON M, Younan D, Kent ST, Mesa-Frias M, et al
     Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC).
     Lung Cancer. 2024;197:107960.
     PubMed     Abstract available
     
     
     
180. ZHENG MZ, Yang ZQ, Cai SL, Zheng LT, et al
     Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug conjugate as targeted therapy for the treatment of lung cancer brain metastasis.
     Lung Cancer. 2024;196:107957.
     PubMed     Abstract available
     
     
     
181. MARSHALL HM, Fong KM
     Lung cancer screening - Time for an update?
     Lung Cancer. 2024;196:107956.
     PubMed     Abstract available
     
     
     
182. MILDNER FO, Sykora MM, Hackl H, Amann A, et al
     Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).
     Lung Cancer. 2024;196:107955.
     PubMed     Abstract available
     
     
     
183. PRESLEY CJ, Tang J, Benedict J, Grogan M, et al
     Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer.
     Lung Cancer. 2024;196:107953.
     PubMed     Abstract available
     
     
     
184. MARKS JA, Gandhi N, Halmos B, Marmarelis ME, et al
     Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
     Lung Cancer. 2024;196:107935.
     PubMed     Abstract available
     
     
     
185. PEETERS S, Lau K, Stefanidis K, Yasufuku K, et al
     New diagnostic and nonsurgical local treatment modalities for early stage lung cancer.
     Lung Cancer. 2024;196:107952.
     PubMed     Abstract available
     
     
     
186. MANSFIELD AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, et al
     Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
     Lung Cancer. 2024;195:107928.
     PubMed     Abstract available
     
     
     
187. LIU KJ, Li HR, Tan QQ, Jiang T, et al
     Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
     Lung Cancer. 2024;195:107933.
     PubMed     Abstract available
     
     
     
188. NASO J, Desai A, Smith CJ, Ashara YP, et al
     Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.
     Lung Cancer. 2024;195:107927.
     PubMed     Abstract available
     
     
     
189. WEI Y, Wu R, Yang S, Cao Y, et al
     MiR-137 mediated high expression of TIGD1 promotes migration, invasion, and suppresses apoptosis of lung adenocarcinoma.
     Lung Cancer. 2024;195:107918.
     PubMed     Abstract available
     
     
     
190. LI Y, Xie F, Zheng Q, Zhang Y, et al
     Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
     Lung Cancer. 2024;195:107930.
     PubMed     Abstract available
     
     
     
191. YING L, Lu T, Tian Y, Guo H, et al
     A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel.
     Lung Cancer. 2024;195:107902.
     PubMed     Abstract available
     
     
     
192. ALIREZAIE N, Chong AL, Kommoss FKF, Sabbaghian N, et al
     Exomic and epigenomic analysis of pulmonary blastoma.
     Lung Cancer. 2024;195:107916.
     PubMed     Abstract available
     
     
     
193. OTTE N, Fraune E, Cetiner Y, Felten MK, et al
     Asbestos Surveillance Program Aachen (ASPA): Cancer mortality among asbestos exposed power industry workers.
     Lung Cancer. 2024;195:107899.
     PubMed     Abstract available
     
     
     
194. LU S, Zhang Y, Zhang G, Zhou J, et al
     Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
     Lung Cancer. 2024;195:107901.
     PubMed     Abstract available
     
     
     August 2024
195. GRIT GF, van Geffen E, Malmberg R, van Leeuwen R, et al
     Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.
     Lung Cancer. 2024;196:107950.
     PubMed     Abstract available
     
     
     
196. LIAO D, Long M, Zhang J, Wei X, et al
     Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.
     Lung Cancer. 2024;196:107936.
     PubMed     Abstract available
     
     
     
197. FERREIRA M, Swalduz A, Greillier L, du Rusquec P, et al
     Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
     Lung Cancer. 2024;196:107934.
     PubMed     Abstract available
     
     
     
198. MALHOTRA J, Chiappori A, Fujioka N, Hanna NH, et al
     Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
     Lung Cancer. 2024;195:107932.
     PubMed     Abstract available
     
     
     
199. TASOUDIS P, Loufopoulos G, Manaki V, Doerr M, et al
     Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis.
     Lung Cancer. 2024;195:107929.
     PubMed     Abstract available
     
     
     
200. BARSOUK A, Elghawy O, Heidlauf A, Yu C, et al
     Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
     Lung Cancer. 2024;195:107926.
     PubMed     Abstract available
     
     
     
201. RECK M, Dziadziuszko R, Sugawara S, Kao S, et al
     Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
     Lung Cancer. 2024;196:107924.
     PubMed     Abstract available
     
     
     
202. CALVO V, Niazmand E, Carcereny E, Rodriguez-Abreu D, et al
     Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk.
     Lung Cancer. 2024;195:107920.
     PubMed     Abstract available
     
     
     
203. DING Y, Lei S, Wang L, Tang L, et al
     Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis.
     Lung Cancer. 2024;195:107925.
     PubMed     Abstract available
     
     
     
204. TAMIYA A, Osuga M, Harada D, Isa SI, et al
     Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naive advanced non-small cell lung cancer.
     Lung Cancer. 2024;195:107917.
     PubMed     Abstract available
     
     
     
205. BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
     Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
     Lung Cancer. 2024;195:107919.
     PubMed     Abstract available
     
     
     
206. GALLINA FT, Balzano V, Porciello N, Taje R, et al
     Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
     Lung Cancer. 2024;194:107900.
     PubMed    
     
     
     
207. BARGHOUT SH, Zhan LJ, Raptis S, Al-Agha F, et al
     Treatment patterns and outcomes in KRAS(G12C)-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
     Lung Cancer. 2024;194:107898.
     PubMed     Abstract available
     
     
     
208. OYA Y, Imaizumi K, Mitsudomi T
     The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?
     Lung Cancer. 2024;194:107886.
     PubMed     Abstract available
     
     
     
209. WESPISER M, Swalduz A, Perol M
     Treatment sequences in EGFR mutant advanced NSCLC.
     Lung Cancer. 2024;194:107895.
     PubMed     Abstract available
     
     
     
210. WANG Q, Liu H, Xu Z, Zhang L, et al
     Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
     Lung Cancer. 2024;194:107888.
     PubMed     Abstract available
     
     
     
211. HUANG S, Cao C, Guo L, Li C, et al
     Comparison of the variability and diagnostic efficacy of respiratory-gated PET/CT based radiomics features with ungated PET/CT in lung lesions.
     Lung Cancer. 2024;194:107889.
     PubMed     Abstract available
     
     
     
212. DOUMA LH, Baas P, de Gooijer CJ
     First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
     Lung Cancer. 2024;194:107891.
     PubMed    
     
     
     
213. XU Y, Zhang Y, Qiang H, Zhong H, et al
     Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC.
     Lung Cancer. 2024;194:107892.
     PubMed     Abstract available
     
     
     
214. NIEDERMAIER B, Kou Y, Tong E, Eichinger M, et al
     CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis.
     Lung Cancer. 2024;194:107890.
     PubMed     Abstract available
     
     
     
215. SPEEL EM, Dafni U, Thunnissen E, Hendrik Ruschoff J, et al
     ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
     Lung Cancer. 2024;194:107860.
     PubMed     Abstract available
     
     
     
216. KIM YJ, Kim S, Kim TM, Suh KJ, et al
     A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
     Lung Cancer. 2024;194:107870.
     PubMed     Abstract available
     
     
     
217. BYLICKI O, Guisier F, Scherpereel A, Daniel C, et al
     Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
     Lung Cancer. 2024;194:107866.
     PubMed     Abstract available
     
     
     
218. OGAWA H, Koga T, Pham NA, Bernards N, et al
     Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma.
     Lung Cancer. 2024;194:107863.
     PubMed     Abstract available
     
     
     
219. PROVENCIO M, Robado de Lope L, Serna-Blasco R, Nadal E, et al
     BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
     Lung Cancer. 2024;194:107865.
     PubMed     Abstract available
     
     
     
220. ARRIETA O, Caballe-Perez E, Hernandez-Pedro N, Romero-Nunez E, et al
     Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study.
     Lung Cancer. 2024;194:107864.
     PubMed     Abstract available
     
     
     July 2024
221. CASIRAGHI M, Cara A, Mazzella A, Girelli L, et al
     1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience.
     Lung Cancer. 2024;195:107903.
     PubMed     Abstract available
     
     
     
222. ZHENG Q, Lin X, Qi W, Yin J, et al
     NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China.
     Lung Cancer. 2024;194:107897.
     PubMed     Abstract available
     
     
     
223. FUJIMOTO D, Hayashi H, Murotani K, Toi Y, et al
     Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).
     Lung Cancer. 2024;194:107896.
     PubMed     Abstract available
     
     
     
224. ASAO T, Shukuya T, Uemura K, Kitadai R, et al
     Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospectiv
     Lung Cancer. 2024;194:107894.
     PubMed     Abstract available
     
     
     
225. BELLUOMINI L, Cesta Incani U, Smimmo A, Avancini A, et al
     Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation.
     Lung Cancer. 2024;194:107893.
     PubMed     Abstract available
     
     
     
226. JACOB M, Fournel P, Tissot C, Cadranel J, et al
     A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
     Lung Cancer. 2024;194:107868.
     PubMed     Abstract available
     
     
     
227. ZANDWIJK NV, Frank AL, Reid G, Dimitri Roe O, et al
     Asbestos-Related lung Cancer: An underappreciated oncological issue.
     Lung Cancer. 2024;194:107861.
     PubMed     Abstract available
     
     
     
228. PONS-TOSTIVINT E, Ezzedine R, Goronflot T, Crequit P, et al
     Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study.
     Lung Cancer. 2024;194:107887.
     PubMed     Abstract available
     
     
     
229. IZUMI M, Costa DB, Kobayashi SS
     Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.
     Lung Cancer. 2024;194:107885.
     PubMed     Abstract available
     
     
     
230. LI R, Xu Y, Zhao J, Zhang L, et al
     Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis.
     Lung Cancer. 2024;194:107884.
     PubMed     Abstract available
     
     
     
231. YOSHIZAKI C, Yoshida Y, Nohmi S, Go Y, et al
     EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.
     Lung Cancer. 2024;194:107869.
     PubMed     Abstract available
     
     
     
232. DE BRUYCKER A, Schneiders F, Gulstene S, Moghanaki D, et al
     Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights.
     Lung Cancer. 2024;193:107848.
     PubMed     Abstract available
     
     
     
233. SAW SPL, Low YF, Lai GGY, Chan LL, et al
     Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
     Lung Cancer. 2024;193:107856.
     PubMed     Abstract available
     
     
     
234. ARMATO SG 3RD, Katz SI, Frauenfelder T, Jayasekera G, et al
     Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group.
     Lung Cancer. 2024;193:107832.
     PubMed     Abstract available
     
     
     
235. BORGHAEI H, Pundole X, Sangare L, Anderson E, et al
     Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study.
     Lung Cancer. 2024;193:107819.
     PubMed     Abstract available
     
     
     
236. FRANK AL, van Zandwijk N
     Asbestos history and use.
     Lung Cancer. 2024;193:107828.
     PubMed     Abstract available
     
     
     
237. ERNST SM, van Marion R, von der Thusen JH, Dubbink HJ, et al
     Exploring the use of circulating tumor DNA for mutational signature analysis.
     Lung Cancer. 2024;193:107844.
     PubMed    
     
     
     June 2024
238. BLANCO-VILLAR ML, Exposito-Hernandez J, Navarro-Moreno E, Lopez Martin JM, et al
     Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study.
     Lung Cancer. 2024;194:107867.
     PubMed     Abstract available
     
     
     
239. NISHIO M, Watanabe S, Udagawa H, Aragane N, et al
     Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer.
     Lung Cancer. 2024 Jun 28:107859. doi: 10.1016/j.lungcan.2024.107859.
     PubMed     Abstract available
     
     
     
240. BUM LEE J, Huang Y, Oya Y, Nutzinger J, et al
     Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.
     Lung Cancer. 2024;194:107862.
     PubMed     Abstract available
     
     
     
241. BEN-ARYE E, Gressel O, Lifshitz S, Peled N, et al
     Integrative oncology for patients with lung cancer: A prospective pragmatic controlled trial.
     Lung Cancer. 2024;193:107857.
     PubMed     Abstract available
     
     
     
242. KLEBE S, Rathi V, Russell PA
     Lung cancer caused by asbestos: What a reporting pathologist needs to know.
     Lung Cancer. 2024;195:107849.
     PubMed     Abstract available
     
     
     
243. METINTAS M, Ak G, Metintas S
     Environmental asbestos exposure and lung cancer.
     Lung Cancer. 2024;194:107850.
     PubMed     Abstract available
     
     
     
244. ASANO Y, Yamamoto N, Demura S, Hayashi K, et al
     Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases.
     Lung Cancer. 2024;193:107858.
     PubMed     Abstract available
     
     
     
245. TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al
     Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platin
     Lung Cancer. 2024 Jun 17:107852. doi: 10.1016/j.lungcan.2024.107852.
     PubMed    
     
     
     
246. CUPPENS K, Du Pont B, Knegjens J, Maes B, et al
     Immune checkpoint inhibition in early-stage non-small cell lung cancer.
     Lung Cancer. 2024;193:107855.
     PubMed     Abstract available
     
     
     
247. APTEKAR J, Jain R, Korytowsky B, Shafquat A, et al
     Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis.
     Lung Cancer. 2024;193:107854.
     PubMed     Abstract available
     
     
     
248. ARRIETA O
     In response to "On the Hispanic paradox in lung cancer".
     Lung Cancer. 2024;193:107853.
     PubMed    
     
     
     
249. GAO X, Tan H, Zhu M, Zhang G, et al
     Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis.
     Lung Cancer. 2024;193:107851.
     PubMed     Abstract available
     
     
     
250. MAHMOOD K, Wang H, Ji Z, Giovacchini CX, et al
     Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing.
     Lung Cancer. 2024;193:107847.
     PubMed     Abstract available
     
     
     
251. HUANG L, Petersen RH
     Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer.
     Lung Cancer. 2024;193:107846.
     PubMed     Abstract available
     
     
     
252. GOTO E, Taki T, Nomura K, Miyakami Y, et al
     Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
     Lung Cancer. 2024;192:107830.
     PubMed     Abstract available
     
     
     
253. LI M, Zhang Y, Zhou P, Miao Y, et al
     Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor.
     Lung Cancer. 2024;192:107825.
     PubMed     Abstract available
     
     
     
254. VORUGANTI MADDALI IS, Cunningham C, McLeod L, Bahig H, et al
     Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study.
     Lung Cancer. 2024;192:107822.
     PubMed     Abstract available
     
     
     
255. SHI M, Pang L, Zhou H, Mo S, et al
     Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
     Lung Cancer. 2024;192:107818.
     PubMed     Abstract available
     
     
     
256. SZENTKERESZTY M, Ladanyi A, Galffy G, Tovari J, et al
     Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma.
     Lung Cancer. 2024;192:107824.
     PubMed     Abstract available
     
     
     
257. CHEN Q, Xia L, Wang J, Zhu S, et al
     EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.
     Lung Cancer. 2024;192:107815.
     PubMed     Abstract available
     
     
     
258. SHAH R, Sun L, Ridge CA
     Image guided lung biopsy.
     Lung Cancer. 2024;192:107803.
     PubMed     Abstract available
     
     
     
259. MARTIN A, Carton M, Thery L, Burnod A, et al
     Palliative care integration and end-of-life care intensity for patients with NSCLC.
     Lung Cancer. 2024;192:107800.
     PubMed     Abstract available
     
     
     
260. ISHIDOYA M, Makiguchi T, Tanaka H, Miura T, et al
     Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
     Lung Cancer. 2024;192:107790.
     PubMed     Abstract available
     
     
     
261. KLOTZ LV, Casjens S, Johnen G, Taeger D, et al
     Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients.
     Lung Cancer. 2024;192:107802.
     PubMed     Abstract available
     
     
     May 2024
262. AMARI L, Tomasini P, Dantony E, Rousseau-Bussac G, et al
     Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC
     Lung Cancer. 2024;193:107843.
     PubMed     Abstract available
     
     
     
263. PENG L, Lidan H, Cuicui Z, Zhe Z, et al
     DNA double-strand break repair capacity and its pathway gene variants predict the risk and prognosis of lung cancer.
     Lung Cancer. 2024;192:107831.
     PubMed     Abstract available
     
     
     
264. KE H, Kao S, van Zandwijk N, Rasko JEJ, et al
     Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer.
     Lung Cancer. 2024;192:107829.
     PubMed     Abstract available
     
     
     
265. LUNDBERG FE, Ekman S, Johansson ALV, Engholm G, et al
     Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies.
     Lung Cancer. 2024;192:107826.
     PubMed     Abstract available
     
     
     
266. HUANG Z, Zhang Y, Xu Q, Song L, et al
     Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
     Lung Cancer. 2024;192:107827.
     PubMed     Abstract available
     
     
     
267. LI Y, Wong M, Zhan L, Corke L, et al
     Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort.
     Lung Cancer. 2024;192:107823.
     PubMed     Abstract available
     
     
     
268. BARAMIDZE A, Makharadze T, Gogishvili M, Melkadze T, et al
     Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
     Lung Cancer. 2024;193:107821.
     PubMed     Abstract available
     
     
     
269. FELIP E, Metro G, Tan DSW, Wolf J, et al
     Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
     Lung Cancer. 2024;192:107820.
     PubMed     Abstract available
     
     
     
270. NADAL E, Rifi N, Kane S, Mbacke S, et al
     Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
     Lung Cancer. 2024;192:107816.
     PubMed     Abstract available
     
     
     
271. WANG Z, Li X, Chen J, Hua Y, et al
     The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma.
     Lung Cancer. 2024;192:107817.
     PubMed     Abstract available
     
     
     
272. WANG L, Li L, Zhou X, Zhang D, et al
     Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
     Lung Cancer. 2024;191:107797.
     PubMed    
     
     
     
273. LU YF, Chang YH, Chen YJ, Hsieh MS, et al
     Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma.
     Lung Cancer. 2024;191:107791.
     PubMed     Abstract available
     
     
     
274. CHOUR A, Basse C, Lebosse F, Bonte PE, et al
     Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
     Lung Cancer. 2024;191:107789.
     PubMed     Abstract available
     
     
     
275. MIYAKOSHI J, Yoshida T, Kashima J, Shirasawa M, et al
     Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
     Lung Cancer. 2024;191:107788.
     PubMed     Abstract available
     
     
     
276. NISHIMURA T, Fujimoto H
     Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?
     Lung Cancer. 2024;191:107561.
     PubMed    
     
     
     
277. HOCKING AJ, Mortimer LA, Farrall AL, Russell PA, et al
     Establishing mesothelioma patient-derived organoid models from malignant pleural effusions.
     Lung Cancer. 2024;191:107542.
     PubMed     Abstract available
     
     
     
278. LIU G, Mazieres J, Stratmann J, Ou SI, et al
     A pragmatic guide for management of adverse events associated with lorlatinib.
     Lung Cancer. 2024;191:107535.
     PubMed     Abstract available
     
     
     April 2024
279. OKAHISA M, Udagawa H, Matsumoto S, Kato T, et al
     Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
     Lung Cancer. 2024;191:107798.
     PubMed     Abstract available
     
     
     
280. ZHANG SL, Tian Y, Yu J, Zhang JH, et al
     Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
     Lung Cancer. 2024;191:107799.
     PubMed     Abstract available
     
     
     
281. BADE BC, Zhao J, Li F, Tanoue L, et al
     Trends and predictors of Quality of Life in lung cancer survivors.
     Lung Cancer. 2024;191:107793.
     PubMed     Abstract available
     
     
     
282. LIU S, Graves N, Tan AC
     The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
     Lung Cancer. 2024;191:107794.
     PubMed     Abstract available
     
     
     
283. DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al
     The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
     Lung Cancer. 2024;191:107792.
     PubMed     Abstract available
     
     
     
284. MALAPELLE U, Passiglia F, Pepe F, Pisapia P, et al
     The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
     Lung Cancer. 2024;191:107787.
     PubMed     Abstract available
     
     
     
285. TAVERNA JA, Hung CN, Williams M, Williams R, et al
     Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
     Lung Cancer. 2024;190:107533.
     PubMed     Abstract available
     
     
     
286. JUNG HA, Park B, Park S, Sun JM, et al
     Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
     Lung Cancer. 2024;190:107536.
     PubMed     Abstract available
     
     
     
287. YU T, Zhou X, Li M
     Comment on: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas.
     Lung Cancer. 2024;190:107534.
     PubMed    
     
     
     
288. PANG LL, Zhuang WT, Huang YH, Liao J, et al
     Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.
     Lung Cancer. 2024;190:107528.
     PubMed     Abstract available
     
     
     
289. DAMHUIS RAM, Dickhoff C, Bahce I, Senan S, et al
     Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
     Lung Cancer. 2024;190:107532.
     PubMed     Abstract available
     
     
     
290. SLATORE CG, Hooker ER, Shull S, Golden SE, et al
     Association of patient and health care organization factors with incidental nodule guidelines adherence: A multi-system observational study.
     Lung Cancer. 2024;190:107526.
     PubMed     Abstract available
     
     
     
291. SUN L, Handorf EA, Zhou Y, Borghaei H, et al
     Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
     Lung Cancer. 2024;190:107510.
     PubMed     Abstract available
     
     
     
292. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
     Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
     Lung Cancer. 2024;190:107513.
     PubMed     Abstract available
     
     
     
293. HONG DS, Cappuzzo F, Chul Cho B, Dowlati A, et al
     Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
     Lung Cancer. 2024;190:107512.
     PubMed     Abstract available
     
     
     March 2024
294. GABRIEL L, McVeigh T, Macmahon S, Avila Z, et al
     Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family.
     Lung Cancer. 2024;191:107543.
     PubMed     Abstract available
     
     
     
295. LYHNE CHRISTENSEN N, Gouliaev A, McPhail S, Lyratzopoulos G, et al
     Lung cancer among the Elderly in Denmark - A comprehensive population-based cohort study.
     Lung Cancer. 2024;191:107555.
     PubMed     Abstract available
     
     
     
296. SUN M, Feng Q, Yan Q, Zhao H, et al
     Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer.
     Lung Cancer. 2024;190:107541.
     PubMed     Abstract available
     
     
     
297. TOZUKA T, Noro R, Mizutani H, Kurimoto F, et al
     Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
     Lung Cancer. 2024;191:107540.
     PubMed     Abstract available
     
     
     
298. RODRIGUEZ J
     On the Hispanic paradox in lung cancer.
     Lung Cancer. 2024;190:107537.
     PubMed    
     
     
     
299. GUDINA AT, Kamen C, Hardy SJ, Kehoe L, et al
     Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals.
     Lung Cancer. 2024;191:107539.
     PubMed     Abstract available
     
     
     
300. PU X, Xiao Z, Li J, Wu Z, et al
     Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
     Lung Cancer. 2024;191:107538.
     PubMed     Abstract available
     
     
     
301. WALLACE ND, Alexander M, Xie J, Ball D, et al
     The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
     Lung Cancer. 2024;190:107531.
     PubMed     Abstract available
     
     
     
302. KIM DW, Chul Cho B, Pachipala K, Kim SW, et al
     Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
     Lung Cancer. 2024;190:107530.
     PubMed     Abstract available
     
     
     
303. CONNOR WELLS J, Mullin MM, Ho C, Melosky B, et al
     Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.
     Lung Cancer. 2024;190:107529.
     PubMed     Abstract available
     
     
     
304. KRAUS KM, Oreshko M, Schnabel JA, Bernhardt D, et al
     Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation.
     Lung Cancer. 2024;189:107507.
     PubMed     Abstract available
     
     
     
305. KAIRA K, Imai H, Kagamu H
     Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.
     Lung Cancer. 2024;189:107501.
     PubMed    
     
     
     
306. ZHOU P, Fu Y, Tang Y, Jiang L, et al
     Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
     Lung Cancer. 2024;189:107471.
     PubMed     Abstract available
     
     
     
307. MOLINA TJ, Roden AC, Szolkowska M, Shimizu S, et al
     International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG study.
     Lung Cancer. 2024;189:107479.
     PubMed     Abstract available
     
     
     
308. KLOKER LD, Sidiras M, Flaadt T, Brecht IB, et al
     Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
     Lung Cancer. 2024;189:107496.
     PubMed     Abstract available
     
     
     
309. FITZGERALD SM
     Resolving asbestos and ultrafine particulate definitions with carcinogenicity.
     Lung Cancer. 2024;189:107478.
     PubMed     Abstract available
     
     
     
310. STARES M, Doyle E, Chapple S, Raynes G, et al
     Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 >/= 50 % progressing on first-line pembrolizumab.
     Lung Cancer. 2024;189:107497.
     PubMed     Abstract available
     
     
     
311. CHEN Y, Chen H, Yu R, Zeng X, et al
     Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.
     Lung Cancer. 2024;189:107476.
     PubMed     Abstract available
     
     
     February 2024
312. GOULIAEV A, Ali F, Jakobsen E, Dalton SO, et al
     The Danish lung cancer registry: A nationwide validation study.
     Lung Cancer. 2024;190:107527.
     PubMed     Abstract available
     
     
     
313. LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al
     Association between surgical quality and long-term survival in lung cancer.
     Lung Cancer. 2024;190:107511.
     PubMed     Abstract available
     
     
     
314. SAEKI Y, Maki N, Nemoto T, Inada K, et al
     Lung cancer detection in perioperative patients' exhaled breath with nanomechanical sensor array.
     Lung Cancer. 2024;190:107514.
     PubMed     Abstract available
     
     
     
315. CHUL CHO B, Han JY, Hyeong Lee K, Lee YG, et al
     Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
     Lung Cancer. 2024;190:107509.
     PubMed     Abstract available
     
     
     
316. BAPTISTE OUDART J, Garinet S, Leger C, Barlesi F, et al
     STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
     Lung Cancer. 2024;190:107508.
     PubMed     Abstract available
     
     
     
317. BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al
     Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
     Lung Cancer. 2024;190:107506.
     PubMed     Abstract available
     
     
     
318. SAAL J, Bald T, Eckstein M, Ralser DJ, et al
     Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
     Lung Cancer. 2024;189:107505.
     PubMed     Abstract available
     
     
     
319. LAESEKE P, Ng C, Naghi A, Wright GWJ, et al
     Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung Cancer: Don't Put the Cart before the stereotactic Horse.
     Lung Cancer. 2024;189:107504.
     PubMed    
     
     
     
320. WANG S, Hao X, Dai L, Lou N, et al
     Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
     Lung Cancer. 2024;189:107503.
     PubMed     Abstract available
     
     
     
321. SAIGI M, Mate JL, Carcereny E, Martinez-Cardus A, et al
     HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
     Lung Cancer. 2024;189:107502.
     PubMed     Abstract available
     
     
     
322. KUNIMASA K, Tamiya M, Inoue T, Kawamura T, et al
     Clinical application of the Lung Cancer Compact Panel(TM) using various types of cytological specimens in patients with lung cancer.
     Lung Cancer. 2024;189:107498.
     PubMed     Abstract available
     
     
     
323. LIU SV, Frohn C, Minasi L, Fernamberg K, et al
     Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
     Lung Cancer. 2024;188:107469.
     PubMed     Abstract available
     
     
     
324. ZHANG YH, Liu XS, Gao Y, Yuan LL, et al
     SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with (18)F-FDG metabolic parameters.
     Lung Cancer. 2024;188:107449.
     PubMed     Abstract available
     
     
     
325. KITAGAWA S, Zenke Y, Taki T, Aokage K, et al
     Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
     Lung Cancer. 2024;188:107453.
     PubMed     Abstract available
     
     
     
326. BURNS L, Tukachinsky H, Raskina K, Huang RSP, et al
     Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
     Lung Cancer. 2024;188:107454.
     PubMed     Abstract available
     
     
     January 2024
327. WANG Y, Hu C, Yu H, Hu J, et al
     Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
     Lung Cancer. 2024;189:107495.
     PubMed     Abstract available
     
     
     
328. HUANG S, Zhao M, Li S, Chen T, et al
     Incorporation of the lepidic component as an additional pathological T descriptor for non-small cell lung cancer: Data from 3335 cases of lung adenocarcinoma.
     Lung Cancer. 2024;189:107472.
     PubMed     Abstract available
     
     
     
329. GENET SAAM, Visser E, Youssef-El Soud M, Belderbos HNA, et al
     Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals.
     Lung Cancer. 2024;189:107477.
     PubMed     Abstract available
     
     
     
330. WU H, Zhang Q, Zhai W, Chen Y, et al
     Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
     Lung Cancer. 2024;188:107475.
     PubMed     Abstract available
     
     
     
331. VAN ZANDWIJK N, Frank AL
     A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC).
     Lung Cancer. 2024 Jan 17:107474. doi: 10.1016/j.lungcan.2024.107474.
     PubMed    
     
     
     
332. PAZ-ARES L, Goto Y, Wan-Teck Lim D, Halmos B, et al
     Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase
     Lung Cancer. 2024;189:107451.
     PubMed     Abstract available
     
     
     
333. NORITAKE O, Nakamura S, Kinoshita F, Aokage K, et al
     Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis.
     Lung Cancer. 2024;188:107470.
     PubMed     Abstract available
     
     
     
334. CHIANG CL, Huang HC, Luo YH, Shen CI, et al
     Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
     Lung Cancer. 2024;188:107473.
     PubMed     Abstract available
     
     
     
335. ZHAO S, Ma Y, Liu L, Fang J, et al
     Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
     Lung Cancer. 2024;188:107468.
     PubMed     Abstract available
     
     
     
336. PASSIGLIA F, Lucia Reale M, Lo Russo G, Pasello G, et al
     Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
     Lung Cancer. 2024;187:107444.
     PubMed     Abstract available
     
     
     
337. MIKUBO M, Tamagawa S, Kondo Y, Hayashi S, et al
     Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management.
     Lung Cancer. 2024;187:107445.
     PubMed     Abstract available
     
     
     
338. GAO J, Ao Y, Wang S, Chen Z, et al
     WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors.
     Lung Cancer. 2024;187:107446.
     PubMed     Abstract available
     
     
     
339. GAO L, Ai X, Lu S
     ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
     Lung Cancer. 2024;187:107443.
     PubMed     Abstract available
     
     
     
340. DUMOULIN DW, Douma LH, Hofman MM, van der Noort V, et al
     Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
     Lung Cancer. 2024;187:107440.
     PubMed     Abstract available
     
     
     
341. LEBOUILLE-VELDMAN AB, Taros TN, Nawabi NLA, Mekary RA, et al
     Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases.
     Lung Cancer. 2024;187:107425.
     PubMed     Abstract available
     
     
     December 2023
342. CHENG Y, Wu L, Huang D, Wang Q, et al
     Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
     Lung Cancer. 2023;188:107455.
     PubMed     Abstract available
     
     
     
343. SAKATA Y, Saito G, Sakata S, Oya Y, et al
     Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
     Lung Cancer. 2023 Dec 29:107450. doi: 10.1016/j.lungcan.2023.107450.
     PubMed    
     
     
     
344. PETERS S, Trigo J, Besse B, Moreno V, et al
     Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval >/=30 days and without central nervous metastases.
     Lung Cancer. 2023;188:107448.
     PubMed     Abstract available
     
     
     
345. TAKAM KAMGA P, Mayenga M, Sebane L, Costantini A, et al
     Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
     Lung Cancer. 2023;188:107447.
     PubMed     Abstract available
     
     
     
346. STUART CM, Dyas AR, Bronsert MR, Velopulos CG, et al
     The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small Cell Lung Cancer.
     Lung Cancer. 2023;188:107452.
     PubMed     Abstract available
     
     
     
347. GRIDELLI C, Peters S, Mok T, Garassino M, et al
     Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
     Lung Cancer. 2023;187:107441.
     PubMed     Abstract available
     
     
     
348. CHO BC, Chiu CH, Massarelli E, Buchschacher GL, et al
     Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
     Lung Cancer. 2023;188:107442.
     PubMed     Abstract available
     
     
     
349. WANG L, Diao M, Zhang Z, Jiang M, et al
     Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
     Lung Cancer. 2023;187:107439.
     PubMed     Abstract available
     
     
     
350. CAVAZZONI A, Digiacomo G, Volta F, Alfieri R, et al
     PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).
     Lung Cancer. 2023;187:107438.
     PubMed     Abstract available
     
     
     
351. NASH J, Brims F
     International standards of care in thoracic oncology: A narrative review of clinical quality indicators.
     Lung Cancer. 2023;186:107421.
     PubMed     Abstract available
     
     
     
352. AKRAM F, Wolf JL, Trandafir TE, Dingemans AC, et al
     Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies.
     Lung Cancer. 2023;186:107413.
     PubMed     Abstract available
     
     
     
353. LIU Z, Wu Q, Li W, Li P, et al
     A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
     Lung Cancer. 2023;186:107386.
     PubMed     Abstract available
     
     
     
354. LINGLING X, Maoxi C, Wei Y, Jieting Z, et al
     Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
     Lung Cancer. 2023;186:107415.
     PubMed     Abstract available
     
     
     
355. SCHMALZ L, Bloomer C, Zhang W, Petty W, et al
     Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
     Lung Cancer. 2023;186:107400.
     PubMed     Abstract available
     
     
     
356. YIN X, Li J, Chen B, Liu K, et al
     The predictive value of (18)F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy.
     Lung Cancer. 2023;186:107389.
     PubMed     Abstract available
     
     
     
357. SUN J, Zhang L, Hu B, Du Z, et al
     Deep learning-based solid component measuring enabled interpretable prediction of tumor invasiveness for lung adenocarcinoma.
     Lung Cancer. 2023;186:107392.
     PubMed     Abstract available
     
     
     November 2023
358. SCHULER A, Huser J, Schmid S, Schar S, et al
     Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
     Lung Cancer. 2023;187:107427.
     PubMed     Abstract available
     
     
     
359. SAKATA Y, Saito G, Sakata S, Oya Y, et al
     Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
     Lung Cancer. 2023;186:107426.
     PubMed     Abstract available
     
     
     
360. LIVANOU ME, Syrigos NK, Montgomery A, Moeckel C, et al
     Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report.
     Lung Cancer. 2023;186:107424.
     PubMed     Abstract available
     
     
     
361. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
     Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
     Lung Cancer. 2023;186:107422.
     PubMed     Abstract available
     
     
     
362. KOCHER WULFECK M, Plesner S, Herndon JE 2nd, Christensen JD, et al
     Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.
     Lung Cancer. 2023;186:107420.
     PubMed     Abstract available
     
     
     
363. MAJEM M, Basch E, Cella D, Garon EB, et al
     Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.
     Lung Cancer. 2023;187:107419.
     PubMed     Abstract available
     
     
     
364. KATO T, Casarini I, Cobo M, Faivre-Finn C, et al
     Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
     Lung Cancer. 2023;187:107414.
     PubMed     Abstract available
     
     
     October 2023
365. LIU SV, Mok TSK, Nabet BY, Mansfield AS, et al
     Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
     Lung Cancer. 2023;186:107418.
     PubMed     Abstract available
     
     
     
366. MANGLAVITI S, Bini M, Apollonio G, Zecca E, et al
     High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
     Lung Cancer. 2023;186:107417.
     PubMed     Abstract available
     
     
     
367. FURUNE S, Ando Y
     Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
     Lung Cancer. 2023;186:107416.
     PubMed    
     
     
     
368. KIM W, Lee SC, Lee WR, Chun S, et al
     The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea.
     Lung Cancer. 2023;186:107412.
     PubMed     Abstract available
     
     
     
369. HUANG S, Wu J, Li S, Li X, et al
     Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
     Lung Cancer. 2023;186:107401.
     PubMed     Abstract available
     
     
     
370. DEHEM A, Mazieres J, Chour A, Guisier F, et al
     Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
     Lung Cancer. 2023;186:107393.
     PubMed     Abstract available
     
     
     
371. MORETTI A, Kovacevic B, Vilmann P, Annema JT, et al
     Performance of EUS-FNA and EUS-B-FNA for the diagnosis of left adrenal glands metastases in patients with lung cancer: A systematic review and meta-analysis.
     Lung Cancer. 2023;186:107391.
     PubMed     Abstract available
     
     
     
372. RYU WK, Yong SH, Lee SH, Gwon HR, et al
     Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer.
     Lung Cancer. 2023;186:107390.
     PubMed     Abstract available
     
     
     
373. RUGGIRELLO M, Valsecchi C, Ledda RE, Sabia F, et al
     Long-term outcomes of lung cancer screening in males and females.
     Lung Cancer. 2023;185:107387.
     PubMed     Abstract available
     
     
     
374. LIM TKH, Skoulidis F, Kerr KM, Ahn MJ, et al
     KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
     Lung Cancer. 2023;184:107293.
     PubMed     Abstract available
     
     
     
375. HO H, Yu SL, Chen HY, Yuan SS, et al
     Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages.
     Lung Cancer. 2023;184:107352.
     PubMed     Abstract available
     
     
     
376. MATSUNAGA T, Suzuki K, Hattori A, Fukui M, et al
     A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor.
     Lung Cancer. 2023;184:107354.
     PubMed     Abstract available
     
     
     
377. LINDBERG K
     Balancing tumour control probability and toxicity in SBRT of ultra-central lung tumours - One step forward.
     Lung Cancer. 2023;184:107343.
     PubMed    
     
     
     
378. GOTO E, Takamochi K, Kishikawa S, Hayashi T, et al
     Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics.
     Lung Cancer. 2023;184:107348.
     PubMed     Abstract available
     
     
     
379. QI R, Fu X, Yu Y, Xu H, et al
     Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
     Lung Cancer. 2023;184:107346.
     PubMed     Abstract available
     
     
     
380. SEKER-CIN H, Tay TKY, Kazdal D, Kluck K, et al
     Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
     Lung Cancer. 2023;184:107317.
     PubMed     Abstract available
     
     
     
381. ZIRANU P, Ferrari PA, Guerrera F, Bertoglio P, et al
     Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score.
     Lung Cancer. 2023;184:107342.
     PubMed     Abstract available
     
     
     
382. YEUNG V, Zaemes J, Yeh J, Giancarlo C, et al
     High levels of expression of Trop-2 in thymic epithelial tumors.
     Lung Cancer. 2023;184:107324.
     PubMed     Abstract available
     
     
     
383. GEMINE RE, Davies GR, Lanyon K, Rees SE, et al
     Quitting smoking improves two-year survival after a diagnosis of non-small cell lung cancer.
     Lung Cancer. 2023;186:107388.
     PubMed     Abstract available
     
     
     September 2023
384. NUTZINGER J, Bum Lee J, Li Low J, Ling Chia P, et al
     Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
     Lung Cancer. 2023;186:107385.
     PubMed     Abstract available
     
     
     
385. CHOW R, McMillan MT, Simone CB 2nd
     Microwave Ablation for Early-Stage Non-Small Cell Lung Cancer: Don't Put the Cart Before the Stereotactic Horse.
     Lung Cancer. 2023;185:107382.
     PubMed    
     
     
     
386. ZHANG Y, Li N, Dong Y, Wang W, et al
     Spatial microenvironment heterogeneity in therapy-naive lung cancer: A concept with more attention needed.
     Lung Cancer. 2023;185:107384.
     PubMed    
     
     
     
387. DAGOGO-JACK I, Kiedrowski LA, Lennerz JK
     Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.
     Lung Cancer. 2023;186:107383.
     PubMed     Abstract available
     
     
     
388. FALCHERO L, Guisier F, Darrason M, Boyer A, et al
     Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
     Lung Cancer. 2023;185:107379.
     PubMed     Abstract available
     
     
     
389. KRAMER T, Kuijvenhoven JC, von der Thusen J, Cohen D, et al
     Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: A randomized clinical trial.
     Lung Cancer. 2023;185:107362.
     PubMed     Abstract available
     
     
     
390. PARRA-MEDINA R, Pablo Castaneda-Gonzalez J, Montoya L, Paula Gomez-Gomez M, et al
     Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis.
     Lung Cancer. 2023;185:107378.
     PubMed     Abstract available
     
     
     
391. GARCIA CAMPELO MR, Wan Y, Lin HM, Chen T, et al
     Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.
     Lung Cancer. 2023;185:107376.
     PubMed     Abstract available
     
     
     
392. BOESCHEN M, Kuhn CK, Wirtz H, Seyfarth HJ, et al
     Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
     Lung Cancer. 2023;184:107361.
     PubMed     Abstract available
     
     
     
393. PORTA C, Pradelli L, Sicari E, Castellani S, et al
     Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
     Lung Cancer. 2023;185:107359.
     PubMed     Abstract available
     
     
     
394. HAN D, Zhu Y, Choudhry AA, Cheng J, et al
     Association of telomere length with risk of lung cancer: A large prospective cohort study from the UK Biobank.
     Lung Cancer. 2023;184:107358.
     PubMed     Abstract available
     
     
     August 2023
395. ZHAO Y, Ma Y, Fan Y, Zhou J, et al
     A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
     Lung Cancer. 2023;184:107355.
     PubMed     Abstract available
     
     
     
396. KU HY, Lin SM, Wang CL, Lo YC, et al
     Impact of pathological nodal staging and tumour differentiation on survival and postoperative radiotherapy in completely resected stage IIIA Non-small-cell lung cancer.
     Lung Cancer. 2023;184:107357.
     PubMed     Abstract available
     
     
     
397. ZENG L, Zhou Y, Xu Q, Huang Z, et al
     Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.
     Lung Cancer. 2023;184:107350.
     PubMed     Abstract available
     
     
     
398. LEFEBVRE AM, Adam J, Nicolazzi C, Larois C, et al
     The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
     Lung Cancer. 2023;184:107356.
     PubMed     Abstract available
     
     
     
399. BOZORGMEHR F, Muller A, Rawluk J, Sianidou M, et al
     Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment?
     Lung Cancer. 2023;184:107340.
     PubMed     Abstract available
     
     
     
400. LEVALLET G, Dubois F, Elie N, Creveuil C, et al
     VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
     Lung Cancer. 2023;182:107287.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.